Investment in China

Merck isn't the first pharmaceutical company to invest in research in China, but it sure is spending a lot more, says ScienceInsider's Hao Xin. The company says it plans to spend about $1.5 billion on R&D in China over the next five years, starting with a staff of 260 in Beijing. Merck already has a commercial headquarters in Shanghai and has built manufacturing facilities in other parts of China, Xin says.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Consulting company McKinsey says diagnostics companies will have to combine genomic data analysis, electronic medical records, effective reimbursement strategies, and regulatory compliance in order to win.

A new report has found that researchers in Africa are still heavily dependent on funding from organizations in the US, Europe, and China, Nature News says.

An article in The Atlantic argues that the progress being made in science isn't keeping pace with the money and time being spent on research.

In Science this week: a CRISPR screen identifies sideroflexin 1 as a requisite component of one-carbon metabolism, and more.